Collaboration Target Information Clause Samples

Collaboration Target Information. In order to assist Licensee with the designation of Collaboration Targets, Licensor will endeavor in good faith and as reasonably practical to promptly provide Licensee with a summary of all material Information in its possession related to any Collaboration Target as requested. (e)Discontinuation of a Collaboration Target or TNF-α Target. At any time during the Term and for any reason, Licensee may discontinue the research program relating to any Collaboration Target or TNF-α Target for any reason and will not be responsible for any future Development Costs incurred after the delivery of discontinuation notice. For purpose of clarity, Licensee will pay any costs actually incurred and accrued but unpaid prior to the date of discontinuation notice and for any Third Party non-terminable costs actually incurred and accrued after the date of discontinuation notice to the extent such non-terminable costs are set forth in the “Collaboration Research Plan” and Licensee is informed that such costs are non-terminable; provided that Licensee shall only pay such non- terminable costs to the extent Licensor used Commercially Reasonable Efforts to mitigate such costs.
Collaboration Target Information. In order to assist Licensee with the designation of Collaboration Targets, Licensor will endeavor in good faith and as reasonably practical to promptly provide Licensee with a summary of all material Information in its possession related to any Collaboration Target as requested.

Related to Collaboration Target Information

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Product Information EPIZYME recognizes that by reason of, inter alia, EISAI’s status as an exclusive licensee in the EISAI Territory under this Agreement, EISAI has an interest in EPIZYME’s retention in confidence of certain information of EPIZYME. Accordingly, until the end of all Royalty Term(s) in the EISAI Territory, EPIZYME shall keep confidential, and not publish or otherwise disclose, and not use for any purpose other than to fulfill EPIZYME’s obligations, or exercise EPIZYME’s rights, hereunder any EPIZYME Know-How Controlled by EPIZYME or EPIZYME Collaboration Know-How, in each case that are primarily applicable to EZH2 or EZH2 Compounds (the “Product Information”), except to the extent (a) the Product Information is in the public domain through no fault of EPIZYME, (b) such disclosure or use is expressly permitted under Section 9.3, or (c) such disclosure or use is otherwise expressly permitted by the terms and conditions of this Agreement. For purposes of Section 9.3, each Party shall be deemed to be both the Disclosing Party and the Receiving Party with respect to Product Information. For clarification, the disclosure by EPIZYME to EISAI of Product Information shall not cause such Product Information to cease to be subject to the provisions of this Section 9.2 with respect to the use and disclosure of such Confidential Information by EPIZYME. In the event this Agreement is terminated pursuant to Article 12, this Section 9.2 shall have no continuing force or effect, but the Product Information, to the extent disclosed by EPIZYME to EISAI hereunder, shall continue to be Confidential Information of EPIZYME, subject to the terms of Sections 9.1 and 9.3 for purposes of the surviving provisions of this Agreement. Each Party shall be responsible for compliance by its Affiliates, and its and its Affiliates’ respective officers, directors, employees and agents, with the provisions of Section 9.1 and this Section 9.2.

  • Research Program The term “

  • Collaboration 31.1 If the Buyer has specified in the Order Form that it requires the Supplier to enter into a Collaboration Agreement, the Supplier must give the Buyer an executed Collaboration Agreement before the Start date. 31.2 In addition to any obligations under the Collaboration Agreement, the Supplier must: 31.2.1 work proactively and in good faith with each of the Buyer’s contractors 31.2.2 co-operate and share information with the Buyer’s contractors to enable the efficient operation of the Buyer’s ICT services and G-Cloud Services